FDA
-
-
-
-
-
-
-
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
-
-
-
-
-
-
-
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
-
-
-
-
-
-
-
Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update
-
-
-
-
-
-
-
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
-
-
-
-
-
-
-
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
-
-
-
251,613 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All